keyword
https://read.qxmd.com/read/38546063/meta-analysis-of-incidence-and-mortality-of-firefighter-cancer-an-update-on-emerging-science
#1
JOURNAL ARTICLE
Sara A Jahnke, Nattinee Jitnarin, Christopher K Haddock, Christopher Kaipust, Walker S Carlos Poston, Brittany S Hollerbach, Carolyn Crisp, Brittni Naylor Metoyer
BACKGROUND: Firefighters are faced with a broad range of toxic exposures during their work, including known and suspected carcinogens. The current study is an update to the previously published meta-analysis of cancer risk among firefighters by Soteriades and colleagues, and focuses on studies published from 2008 to 2020. METHODS: A comprehensive search of the literature was conducted, including electronic databases and bibliographies of recently published papers...
March 1, 2024: Asian Pacific Journal of Cancer Prevention: APJCP
https://read.qxmd.com/read/38544841/patient-reported-outcomes-in-hodgkin-lymphoma-trials-a-systematic-review
#2
Esther Natalie Oliva, Tatyana Ionova, Edward Laane, Mario Csenar, Julia Schroer, Karolin Behringer, Ina Monsef, Annika Oeser, Nicole Skoetz, Sam Salek
BACKGROUND: Lymphoma treatment can lead to long-term consequences such as fatigue, infertility and organ damage. In clinical trials, survival outcomes, clinical response and toxicity are extensively reported while the assessment of treatment on quality of life (QoL) and symptoms is often lacking. OBJECTIVE: We evaluated the use and frequency of patient-reported outcome (PRO) instruments used in randomized controlled trials (RCTs) for Hodgkin lymphoma (HL) and their consistency of reporting...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38543695/initial-efficacy-of-the-covid-19-mrna-vaccine-booster-and-subsequent-breakthrough-omicron-variant-infection-in-patients-with-b-cell-non-hodgkin-s-lymphoma-a-single-center-cohort-study
#3
JOURNAL ARTICLE
Makoto Saito, Akio Mori, Takashi Ishio, Mirei Kobayashi, Shihori Tsukamoto, Sayaka Kajikawa, Emi Yokoyama, Minoru Kanaya, Koh Izumiyama, Haruna Muraki, Masanobu Morioka, Takeshi Kondo
It has been suggested that the effect of coronavirus disease 2019 (COVID-19) booster vaccination in patients with B-cell non-Hodgkin's lymphoma (B-NHL) is inferior to that in healthy individuals. However, differences according to histological subtype or treatment status are unclear. In addition, there has been less research on patients who subsequently develop breakthrough infections. We investigated the effects of the first COVID-19 booster vaccination for patients with B-NHL and the clinical features of breakthrough infections in the Omicron variant era...
February 21, 2024: Viruses
https://read.qxmd.com/read/38542233/b-cell-activation-biomarkers-in-salivary-glands-are-related-to-lymphomagenesis-in-primary-sj%C3%A3-gren-s-disease-a-pilot-monocentric-exploratory-study
#4
JOURNAL ARTICLE
Dario Bruno, Barbara Tolusso, Gianmarco Lugli, Clara Di Mario, Luca Petricca, Simone Perniola, Laura Bui, Roberta Benvenuto, Gianfranco Ferraccioli, Stefano Alivernini, Elisa Gremese
Primary Sjögren's disease is primarily driven by B-cell activation and is associated with a high risk of developing non-Hodgkin's lymphoma (NHL). Over the last few decades, microRNA-155 (miR-155) has arisen as a key regulator of B-cells. Nevertheless, its role in primary Sjögren's disease remains elusive. Thus, the purpose of this study was (i) to explore miR-155, B-cell activating factor (BAFF)-receptor (BAFF-R), and Interleukin 6 receptor (IL-6R) expression in the labial salivary glands (LSG) of patients with primary Sjögren's disease, aiming to identify potential B-cell activation biomarkers related to NHL development...
March 13, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38541877/a-comprehensive-two-decade-analysis-of-lymphoma-incidence-patterns-in-saudi-arabia
#5
JOURNAL ARTICLE
Ahmed M Basudan, Mohammed Althani, Manal Abudawood, Raed Farzan, Yazeed Alshuweishi, Mohammad A Alfhili
Background: Lymphomas account for approximately 10% of all cancer cases among the Saudi population. Even when separated, Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are in the top ten most commonly diagnosed cancers among Saudi men and women. Despite the substantial cost of HL and NHL to public health, the resources to assess their impact are insufficient. This study provides a two-decade detailed assessment of lymphoma incidence trends in the Saudi population. Methods: Analysis of the Saudi Cancer Registry (SCR) data for various incidence metrics from 2001 to 2020 was conducted...
March 13, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38541203/primary-thyroid-lymphoma-a-retrospective-observational-study-in-a-single-institutional-center
#6
JOURNAL ARTICLE
Octavia Vita, Alis Dema, Robert Barna, Remus Cornea, Dan Brebu, Mihaela Vlad, Oana Popa, Ioana Muntean, Diana Szilagyi, Mihaela Iacob, Maria Iordache, Marioara Cornianu, Dorela Codruta Lazureanu
Background and Objectives : primary thyroid lymphoma (PTL) is a rare neoplasm, displaying a variety of histological features. It is often a challenge for pathologists to diagnose this tumor. Materials and Methods : this study is a retrospective analysis of clinical and pathological characteristics of a group of eleven patients (eight women and three men, mean age 68 years, range 50-80 years) diagnosed with PTL. Results : nine patients (81.81%) presented a tumor with progressive growth in the anterior cervical region, usually painless and accompanied by local compressive signs...
March 14, 2024: Medicina
https://read.qxmd.com/read/38541156/reduced-corticosteroid-exposure-is-safe-and-does-not-reduce-disease-control-among-hodgkin-lymphoma-patients-treated-with-escalated-beacopp-ebeacopp
#7
JOURNAL ARTICLE
Ida Hude Dragičević, Sandra Bašić-Kinda, Helena Markotić, Martina Morić-Perić, Dino Dujmović, Ivo Radman, Barbara Dreta, Snježana Dotlić, Ivana Ilić, Lea Galunić Bilić, Margareta Dobrenić, Marko Kralik, Igor Aurer
Background and Objectives : eBEACOPP is the most effective chemotherapy regimen for younger patients with early unfavorable (EU) and advanced-stage (AS) Hodgkin lymphoma (HL), albeit with significant toxicities. The 14-day/cycle prednisone course contributes to side effects, including osteoarticular events like avascular bone necrosis (AVN). Our center has been using eBEACOPP since 2009 for AS and 2014 for EU patients. In 2016, we reduced prednisone treatment to 7-10 days to lessen AVN risk. We analyzed the effects of this approach...
March 2, 2024: Medicina
https://read.qxmd.com/read/38540261/the-possible-role-of-pathogens-and-chronic-immune-stimulation-in-the-development-of-diffuse-large-b-cell-lymphoma
#8
REVIEW
Lajos Gergely, Miklos Udvardy, Arpad Illes
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. The disease is very heterogeneous, with distinct genetic alterations in subtypes. The WHO 2022 5th edition classification identifies several minor groups of large B-cell lymphoma where the pathogenetic role of viruses (like EBV and HHV-8) is identified. Still, most cases fall into the group of DLBCL not otherwise specified (NOS). No review focuses only on this specific lymphoma type in the literature. The pathogenesis of this entity is still not fully understood, but several viruses and bacteria may have a role in the development of the disease...
March 14, 2024: Biomedicines
https://read.qxmd.com/read/38539503/estimation-of-mediastinal-toxicities-after-radiotherapy-for-hodgkin-lymphoma-a-normal-tissue-complication-analysis-of-the-hd16-17-trial-by-the-german-hodgkin-study-group
#9
JOURNAL ARTICLE
Michael Oertel, Priska Hölscher, Dominik Hering, Christopher Kittel, Michael Fuchs, Uwe Haverkamp, Peter Borchmann, Hans Theodor Eich
PURPOSE: Hodgkin lymphoma is a hematologic malignancy with excellent outcomes even in advanced stages. Consequently, the importance of treatment-associated toxicity increases. However, the exact estimation of individualized rates is difficult due to different disease extents, treatment strategies and techniques. The following analysis aims at a pre-treatment estimation of relevant mediastinal toxicities. METHODS: Normal tissue complication probability calculations were used to evaluate the toxicity rates for the heart, lungs and female breast of patients undergoing radiotherapy for early-stage Hodgkin lymphoma...
March 16, 2024: Cancers
https://read.qxmd.com/read/38538318/extranodal-nk-t-cell-lymphoma-with-localized-relapse-in-bone-marrow-of-lower-leg-detected-using-pet-ct
#10
JOURNAL ARTICLE
Takahisa Nakamura, Hiro Tatetsu, Yusuke Higuchi, Shinya Endo, Shinya Shiraishi, Koichi Kawanaka, Daisuke Imakane, Miyu Sonoda, Rie Furuta, Takafumi Shichijo, Yumi Honda, Kennosuke Karube, Yoshiki Mikami, Kisato Nosaka, Masao Matsuoka, Jun-Ichirou Yasunaga
Extranodal natural killer (NK)/T-cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin lymphoma (NHL) with poor prognosis, particularly in relapsed or refractory patients. Thus, timely detection of relapse and appropriate disease management are crucial. We present two patients with ENKTL, wherein positron emission tomography-computed tomography (PET-CT) with total-body coverage after induction therapy, detected newly relapsed regions in the bone marrow of the lower leg prior to progression. Case 1: A 47-year-old woman with nasal obstruction, showing 18F-fluoro-deoxyglucose (FDG) uptake in the nasal cavity (Lugano stage IE)...
2024: Journal of Clinical and Experimental Hematopathology: JCEH
https://read.qxmd.com/read/38534975/expression-patterns-of-gata3-in-classical-hodgkin-lymphoma-a-clinico-pathological-study
#11
JOURNAL ARTICLE
Alexandra Papoudou-Bai, Epameinondas Koumpis, Georgia Karpathiou, Eleftheria Hatzimichael, Panagiotis Kanavaros
GATA3 is a transcription factor involved in T-cell maturation and has been previously shown to be aberrantly overexpressed in malignant Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL). However, the immunophenotypes of the cell types expressing GATA3 have not been precisely characterized so far in cHL tissues. In this single-center retrospective cohort study we analyzed the expression patterns of GATA3 alone and in combination with B, T, NK or macrophage-associated markers in 73 cases with newly diagnosed cHL and investigated for a possible correlation with clinical and laboratory parameters...
February 29, 2024: Diseases (Basel)
https://read.qxmd.com/read/38534887/navigating-lymphomas-through-bcr-signaling-and-double-hit-insights-overview
#12
REVIEW
Antonella Argentiero, Alessandro Andriano, Donatello Marziliano, Vanessa Desantis
Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating from B, T, or NK lymphocytes. They represent approximately 4-5% of new cancer cases and are classified according to the revised WHO system based on cell lineage, morphology, immunophenotype, and genetics. Diagnosis requires adequate biopsy material, though integrated approaches are used for leukemic presentations. Molecular profiling is improving classification and identifying prognostic markers. Indolent NHLs, such as follicular lymphoma and marginal zone lymphoma, typically pursue a non-aggressive clinical course with long survival...
March 21, 2024: Hematology Reports
https://read.qxmd.com/read/38534788/the-opposite-functions-of-cd30-ligand-isoforms
#13
JOURNAL ARTICLE
Ignat Printsev, Elyas Alalli, Janine Bilsborough
TNFSF8/CD30 ligand is a TNF superfamily member expressed on several major immune cell types, including activated monocytes, B, and T cells. The signaling of CD30 ligand through its cognate CD30 receptor has been shown to have effects on cell differentiation, cell death/survival, and cytokine production. The signaling pair has been implicated in hematopoietic malignancies and inflammatory disease, and a chemotherapy-CD30 antibody combination for the treatment of Hodgkin and other lymphomas has been developed...
March 21, 2024: Current Issues in Molecular Biology
https://read.qxmd.com/read/38532527/management-of-vaccinations-in-patients-with-non-hodgkin-lymphoma
#14
REVIEW
Michele Merli, Andrea Costantini, Silvio Tafuri, Davide Fiore Bavaro, Carla Minoia, Erika Meli, Stefano Luminari, Guido Gini
Vaccinations are fundamental tools in preventing infectious diseases, especially in immunocompromised patients like those affected by non-Hodgkin lymphomas (NHLs). The COVID-19 pandemic made clinicians increasingly aware of the importance of vaccinations in preventing potential life-threatening SARS-CoV-2-related complications in NHL patients. However, several studies have confirmed a significant reduction in vaccine-induced immune responses after anti-CD20 monoclonal antibody treatment, thus underscoring the need for refined immunization strategies in NHL patients...
March 26, 2024: British Journal of Haematology
https://read.qxmd.com/read/38532234/stigma-risks-and-benefits-of-medicinal-cannabis-use-among-australians-with-cancer
#15
JOURNAL ARTICLE
Julia N Morris, Jessica Loyer, Jason Blunt
PURPOSE: People with cancer who use medicinal cannabis do so despite risks associated with limited clinical evidence, legalities, and stigma. This study investigated how Australians with cancer rationalise their medicinal cannabis use despite its risks. METHODS: Ten adults (5 males and 5 females; mean age of 53.3) who used cannabis medicinally for their cancer were interviewed in 2021-2022 about how they used and accessed the substance, attitudes and beliefs underpinning their use, and conversations with others about medicinal cannabis...
March 27, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38531760/car-t-cell-therapy-a-collaboration-between-authorized-treatment-centers-and-community-oncologists
#16
REVIEW
Michael R Bishop, Gary E Kay
With the approval of the first CAR T-cell products for hematological malignancies in 2017, these autologous cell therapies have changed the treatment paradigm for patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL), who have a poor prognosis and few effective treatment options. Despite the demonstrated clinical benefit in patients with r/r diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma, many patients who are eligible for CAR T-cell therapies do not receive them or are treated with CAR T cells as a later line of therapy at advanced stages of disease...
February 22, 2024: Seminars in Oncology
https://read.qxmd.com/read/38531057/impact-of-race-and-social-determinants-of-health-on-outcomes-in-patients-with-aggressive-b-cell-nhl-treated-with-car-t
#17
JOURNAL ARTICLE
Reem Karmali, Rushad Machhi, Narendranath Epperla, Geoffrey Shouse, Jason T Romancik, Tamara K Moyo, Vaishalee P Kenkre, Thomas A Ollila, Lindsey A Fitzgerald, Brian T Hess, Kevin A David, Ishan Roy, Joanna C Zurko, Sayan Mullick Chowdhury, Kaitlin Annunzio, Robert Ferdman, Rahul S Bhansali, Elyse I Harris, Jieqi Liu, Imran A Nizamuddin, Shuo Ma, Jonathan Moreira, Jane N Winter, Barbara Pro, Deborah M Stephens, Alexey V Danilov, Nirav N Shah, Jonathon B Cohen, Stefan K Barta, Pallawi Torka, Leo I Gordon
Healthcare disparities driven by multiple social, economic, and/or environmental factors lead to inequalities in health outcomes. CAR-T cell immunotherapy is an effective therapy for relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). However, data are limited on the impact of the convergence of race and social determinants of health on outcomes for patients treated with CAR-T therapy. We examined the impact of interactions between race and insurance type on health care utilization and outcomes in patients treated with CAR-T for aggressive B-NHL...
March 26, 2024: Blood Advances
https://read.qxmd.com/read/38529931/acute-kidney-injury-in-children-with-lymphoma
#18
JOURNAL ARTICLE
Hejia Zhang, Yanlong Duan, Xiaoxue Li, Zhi Chen, Xiaorong Liu
OBJECTIVE: To analyze the epidemiology of acute kidney injury (AKI) in children with lymphoma and to assess the incidence, risk profile of AKI, and effects on renal function in children with lymphoma during their first 30 days of hospitalization. MATERIALS AND METHODS: This was a retrospective screen of electronic hospital and laboratory databases to select hospitalized children who were first diagnosed and treated for lymphoma at Beijing Children's Hospital between 2020 and 2021...
March 26, 2024: Clinical Nephrology
https://read.qxmd.com/read/38521840/post-marketing-surveillance-of-the-safety-and-effectiveness-of-nivolumab-for-classic-hodgkin-lymphoma-in-japan
#19
JOURNAL ARTICLE
Akira Kawasaki, Kiyohiko Hatake, Itaru Matsumura, Koji Izutsu, Tomohiro Hoshino, Ayumi Akamatsu, Akito Kakuuchi, Kensei Tobinai
Nivolumab was approved for relapsed/refractory classic Hodgkin lymphoma (cHL) in Japan in 2016. After its approval, a prospective, non-interventional, observational post-marketing surveillance was initiated to evaluate the safety and effectiveness of nivolumab treatment for up to 12 months in patients with relapsed/refractory cHL. Of 304 registered patients, 288 were included in safety analyses and 282 in effectiveness analyses. There were 191 (66.3%) male patients, median age was 64.0 years, and 54 patients (18...
March 23, 2024: International Journal of Hematology
https://read.qxmd.com/read/38521411/graft-failure-incidence-risk-factors-and-outcomes-in-patients-undergoing-non-myeloablative-allogeneic-hematopoietic-cell-transplantation-using-post-transplant-cyclophosphamide
#20
JOURNAL ARTICLE
Jonaphine Rae Mata, Marianna Zahurak, Natalie Rosen, Amy E DeZern, Richard J Jones, Alexander J Ambinder
BACKGROUND: Graft failure (GF) is a major complication of allogeneic hematopoietic cell transplantation (alloHCT) that results in significant morbidity and mortality. Post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis has emerged as an effective regimen across the spectrum of donor-match settings, but few studies have investigated the characteristics of GF in the setting of PTCy-based GVHD prophylaxis. OBJECTIVES: The objective was to detail the incidence, clinical features, risk factors, and outcomes for patients with primary graft failure (PGF) and secondary graft failure (SGF)...
March 21, 2024: Transplantation and cellular therapy
keyword
keyword
46636
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.